MR-guided focused ultrasound (MRgFUS) developer InSightec has received approval from Japan's Ministry of Health, Labor, and Welfare for its ExAblate MRgFUS system.
The clearance covers the use of ExAblate for pain palliation caused by bone metastases and for advanced treatment of uterine fibroids, according to InSightec shareholder Elbit Imaging. GE Healthcare holds the approval for ExAblate and will distribute the system in Japan, Elbit said.
